外周血炎症指标在慢加急性肝衰竭患者预后评估中的应用

杨学芳; 杨晓庆; 马海文; 施文娟; 万红; 王建云

doi:10.12449/JCH251133

外周血炎症指标在慢加急性肝衰竭患者预后评估中的应用

DOI: 10.12449/JCH251133

兰州市第二人民医院感染科，兰州 730000

基金项目:

甘肃省卫生健康行业科研项目 (GSWSQN2023-11);

北京肝胆相照公益基金会资助项目 (RGGJJ-2021-016)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：A负责设计论文框架，起草论文；B负责实验操作，研究过程的实施；C负责数据收集，统计学分析、绘制图表；D负责论文修改；E负责拟定写作思路，指导撰写文章并最后定稿。

作者贡献声明：杨学芳、杨晓庆撰写论文；马海文、施文娟、万红修改论文；王建云负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
王建云， wjyno.1@163.com （ORCID： 0009-0004-3870-2144）

计量
- 文章访问数: 5
- HTML全文浏览量: 3
- PDF下载量: 4
- 被引次数: 0
出版历程
- 收稿日期: 2025-04-22
- 录用日期: 2025-06-11
- 出版日期: 2025-11-25

Application of peripheral blood inflammatory markers in prognosis evaluation of patients with acute-on-chronic liver failure

Department of Infectious Diseases，The Second People’s Hospital of Lanzhou，Lanzhou 730000，China

Research funding:

Gansu Provincial Health Industry Research Project (GSWSQN2023-11);

Beijing Liver Foundation Funded Project (RGGJJ-2021-016)

More Information

Corresponding author: WANG Jianyun， wjyno.1@163.com （ORCID： 0009-0004-3870-2144）

摘要

摘要: 慢加急性肝衰竭（ACLF）是在慢性肝病基础上发生的严重肝功能障碍，具有病情进展快、预后差、病死率高等特点。炎症指标因在ACLF评估预后中具有重要作用，而成为研究热点。本文综述全身免疫炎症指数、淋巴细胞与白细胞比值、中性粒细胞与淋巴细胞比值、C反应蛋白等炎症指标在ACLF预后评估中的应用进展，探讨其临床价值及未来研究方向，为ACLF患者早期干预和预后管理提供理论依据。
- 慢加急性肝功能衰竭 /
- 炎症 /
- 预后
Abstract: Acute-on-chronic liver failure （ACLF） refers to severe liver dysfunction that occurs on the basis of chronic liver diseases， and it is characterized by rapid disease progression， poor prognosis， and high mortality rate. In recent years， inflammatory markers have become a research hotspot due to their significant role in assessing the prognosis of ACLF. This article reviews the advances in the application of inflammatory markers in assessing the prognosis of ACLF， such as systemic immune inflammatory index， lymphocyte-white blood cell ratio， neutrophil-lymphocyte ratio， and C-reactive protein， and discusses their clinical value and future research directions， in order to provide a theoretical basis for the early intervention and prognosis management of ACLF patients.
- Acute-on-Chronic Liver Failure /
- Inflammation /
- Prognosis

HTML全文

参考文献(50)

[1]	ZACCHERINI G, WEISS E, MOREAU R. Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment[J]. JHEP Rep, 2020, 3( 1): 100176. DOI: 10.1016/j.jhepr.2020.100176.
[2]	QIN G, SHAO JG, ZHU YC, et al. Population-representative incidence of acute-on-chronic liver failure: A prospective cross-sectional study[J]. J Clin Gastroenterol, 2016, 50( 8): 670- 675. DOI: 10.1097/MCG.0000000-000000538.
[3]	WU TZ, LI J, SHAO L, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure[J]. Gut, 2018, 67( 12): 2181- 2191. DOI: 10.1136/gutjnl-2017-314641.
[4]	BESCH C, MICHARD B, ADDEO P, et al. Impact of early remote organ dysfunction on long-term survival after liver transplantation[J]. Clin Res Hepatol Gastroenterol, 2019, 43( 6): 730- 737. DOI: 10.1016/j.clinre.2019.02.016.
[5]	CASULLERAS M, ZHANG IW, LÓPEZ-VICARIO C, et al. Leukocytes, systemic inflammation and immunopathology in acute-on-chronic liver failure[J]. Cells, 2020, 9( 12): 2632. DOI: 10.3390/cells9122632.
[6]	van der POLL T, van de VEERDONK FL, SCICLUNA BP, et al. The immunopathology of sepsis and potential therapeutic targets[J]. Nat Rev Immunol, 2017, 17( 7): 407- 420. DOI: 10.1038/nri.2017.36.
[7]	LISMAN T, LUYENDYK JP. Systemic inflammation and disorders of hemostasis in the AD-ACLF syndrome[J]. J Hepatol, 2021, 74( 5): 1264- 1265. DOI: 10.1016/j.jhep.2020.12.017.
[8]	ARROYO V, ANGELI P, MOREAU R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis[J]. J Hepatol, 2021, 74( 3): 670- 685. DOI: 10.1016/j.jhep.2020.11.048.
[9]	WANG TS, WANG N, ZHANG RZ, et al. Role of immune response and inflammatory injury in the pathogenesis of liver failure[J]. J Clin Hepatol, 2020, 36( 6): 1415- 1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050. 王挺帅, 王娜, 张荣臻, 等. 免疫反应与炎症损伤在肝衰竭发病机制中的作用[J]. 临床肝胆病杂志, 2020, 36( 6): 1415- 1419. DOI: 10.3969/j.issn.1001-5256.2020.06.050.
[10]	CAI YJ, DONG JJ, DONG JZ, et al. A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure[J]. Aliment Pharmacol Ther, 2017, 45( 11): 1413- 1426. DOI: 10.1111/apt.14046.
[11]	KIM JH, KIM SE, SONG DS, et al. Platelet-to-white blood cell ratio is associated with adverse outcomes in cirrhotic patients with acute deterioration[J]. J Clin Med, 2022, 11( 9): 2463. DOI: 10.3390/jcm11092463.
[12]	BERNSMEIER C, CAVAZZA A, FATOUROU EM, et al. Leucocyte ratios are biomarkers of mortality in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure[J]. Aliment Pharmacol Ther, 2020, 52( 5): 855- 865. DOI: 10.1111/apt.15932.
[13]	MA YJ, XU Y, DU LY, et al. Association between systemic immune inflammation index and short term prognosis of acute on chronic liver failure[J]. Sci Rep, 2024, 14: 21535. DOI: 10.1038/s41598-024-72447-3.
[14]	INCICCO S, ANGELI P, PIANO S. Bacterial infections in acute on chronic liver failure[J]. Clin Liver Dis, 2023, 27( 3): 703- 716. DOI: 10.1016/j.cld.2023.03.013.
[15]	PITRE T, JONES A, SU J, et al. Inflammatory biomarkers as independent prognosticators of 28-day mortality for COVID-19 patients admitted to general medicine or ICU wards: A retrospective cohort study[J]. Intern Emerg Med, 2021, 16( 6): 1573- 1582. DOI: 10.1007/s11739-021-02637-8.
[16]	ZHANG Y, CHEN P, ZHU X. Lymphocyte-to-white blood cell ratio is associated with outcome in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. World J Gastroenterol, 2023, 29( 23): 3678- 3687. DOI: 10.3748/wjg.v29.i23.3678.
[17]	XIE YN, HE CY, WANG W. A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis[J]. Ann Med, 2022, 54( 1): 3201- 3210. DOI: 10.1080/07853890.2022.2142277.
[18]	SADATOMO A, INOUE Y, ITO H, et al. Interaction of neutrophils with macrophages promotes IL-1β maturation and contributes to hepatic ischemia-reperfusion injury[J]. J Immunol, 2017, 199( 9): 3306- 3315. DOI: 10.4049/jimmunol.1700717.
[19]	WU W, YAN HD, ZHAO H, et al. Characteristics of systemic inflammation in hepatitis B-precipitated ACLF: Differentiate it from No-ACLF[J]. Liver Int, 2018, 38( 2): 248- 257. DOI: 10.1111/liv.13504.
[20]	CHIRIAC S, STANCIU C, SINGEAP AM, et al. Prognostic value of neutrophil-to-lymphocyte ratio in cirrhotic patients with acute-on-chronic liver failure[J]. Turk J Gastroenterol, 2021, 31( 12): 868- 876. DOI: 10.5152/tjg.2020.19838.
[21]	YAN TH, XIE XH, JIANG JH, et al. Diagnostic and prognostic value of NLR in hepatitis B-related acute-on-chronic liver failure[J]. J Chengde Med Univ, 2021, 38( 5): 379- 382. DOI: 10.15921/j.cnki.cyxb.2021.05.005. 严汀华, 谢雪华, 江金华, 等. NLR在乙肝相关慢加急性肝衰竭诊断及预后预测价值[J]. 承德医学院学报, 2021, 38( 5): 379- 382. DOI: 10.15921/j.cnki.cyxb.2021.05.005.
[22]	SUN J, GUO HY, YU XP, et al. A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2021, 21( 1): 422. DOI: 10.1186/s12876-021-02007-w.
[23]	MAO J, LIU XH, YANG JJ, et al. Research progress on the value of inflammatory and immune indexes in predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure[J/CD]. Chin J Liver Dis(Electronic Version), 2024, 16( 1): 18- 21. DOI: 10.3969/j.issn.1674-7380.2024.01.004. 毛静, 刘鑫华, 杨军杰, 等. 炎症和免疫指标对乙型肝炎病毒感染相关慢加急性肝衰竭预后判断价值研究进展[J/CD]. 中国肝脏病杂志(电子版), 2024, 16( 1): 18- 21. DOI: 10.3969/j.issn.1674-7380.2024.01.004.
[24]	YANG P, XIAO LY, YANG N, et al. The evaluation value of procalcitonin and prothrombin activity in the prognosis of liver failure complicated by infection[J]. Chin J Nosocomiology, 2022, 32( 4): 531- 534. DOI: 10.11816/cn.ni.2022-210509. 杨平, 肖乐尧, 杨娜, 等. 降钙素原和凝血酶原活动度在肝衰竭合并感染预后中的评估价值[J]. 中华医院感染学杂志, 2022, 32( 4): 531- 534. DOI: 10.11816/cn.ni.2022-210509.
[25]	CHEN XQ, LIN ZG. Value of serum PCT, CRP, PTA combined with MELD scoring system in predicting short-term prognosis of ACLF patients[J]. J Med Theory Pract, 2021, 34( 23): 4164- 4166. DOI: 10.19381/j.issn.1001-7585.2021.23.056. 陈小琴, 林志刚. 血清PCT、CRP、PTA联合MELD评分系统预测 ACLF患者短期预后的价值[J]. 医学理论与实践, 2021, 34( 23): 4164- 4166. DOI: 10.19381/j.issn.1001-7585.2021.23.056.
[26]	ZHENG YB, WANG AG, CHEN C, et al. Correlation analysis between serum PCT and liver function parameters in patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 12): 1130- 1133. DOI: 10.3969/j.issn.1005-0264.2021.12.019. 郑义彬, 王爱国, 陈冲, 等. 乙型肝炎病毒相关慢加急性肝衰竭患者血清PCT与肝功能参数的相关性分析[J]. 中西医结合肝病杂志, 2021, 31( 12): 1130- 1133. DOI: 10.3969/j.issn.1005-0264.2021.12.019.
[27]	RUSSO E, GUIZZARDI M, CANALI L, et al. Preoperative systemic inflammatory markers as prognostic factors in differentiated thyroid cancer: A systematic review and meta-analysis[J]. Rev Endocr Metab Disord, 2023, 24( 6): 1205- 1216. DOI: 10.1007/s11154-023-09845-x.
[28]	WANG Y, CHEN Y, HAN YY, et al. Platelet-lymphocyte ratio predicts in-hospital mortality in elderly patients with acute myocardial infarction[J]. Chin Gen Pract, 2023, 26( 33): 4137- 4142. DOI: 10.12114/j.issn.1007-9572.2023.0116. 王瑜, 陈焱, 韩元元, 等. 血小板-淋巴细胞比值可预测老年急性心肌梗死患者住院期间死亡风险[J]. 中国全科医学, 2023, 26( 33): 4137- 4142. DOI: 10.12114/j.issn.1007-9572.2023.0116.
[29]	FAN RJ, LIN WC, GOU MM, et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in bile tract carcinoma patients treated with immune checkpoint inhibitors[J]. Acad J Chin PLA Med Sch, 2022, 43( 3): 296- 302. DOI: 10.3969/j.issn.2095-5227.2022.03.010. 范润佳, 林万程, 苟苗苗, 等. 血小板/淋巴细胞比值和中性粒细胞/淋巴细胞比值与胆道癌患者PD-1抑制剂治疗的预后分析[J]. 解放军医学院学报, 2022, 43( 3): 296- 302. DOI: 10.3969/j.issn.2095-5227.2022.03.010.
[30]	SHEN YF, HUANG XM, ZHANG WM. Platelet-to-lymphocyte ratio as a prognostic predictor of mortality for sepsis: Interaction effect with disease severity-a retrospective study[J]. BMJ Open, 2019, 9( 1): e022896. DOI: 10.1136/bmjopen-2018-022896.
[31]	MIN J, LU JH, JI XW, et al. Predictive value of platelet-lymphocyte ratio in the prognosis of patients with sepsis[J]. Zhejiang Med J, 2022, 44( 21): 2256- 2259, 2264. DOI: 10.12056/j.issn.1006-2785.2022.44.21.2022-829. 闵婕, 陆建红, 姬晓伟, 等. 血小板与淋巴细胞比值对脓毒症患者预后的评估价值[J]. 浙江医学, 2022, 44( 21): 2256- 2259, 2264. DOI: 10.12056/j.issn.1006-2785.2022.44.21.2022-829.
[32]	WANG LX, CHE X, HUANG R, et al. Value of platelet to lymphocyte ratio in early screening and prognosis prediction of influenza viral sepsis[J]. Acad J Chin PLA Med Sch, 2024, 45( 6): 578- 583. DOI: 10.12435/j.issn.2095-5227.2024.089. 王乐霄, 车霄, 黄锐, 等. 血小板计数/淋巴细胞计数比值在流感病毒性脓毒症早期筛查及预后预测中的应用价值[J]. 解放军医学院学报, 2024, 45( 6): 578- 583. DOI: 10.12435/j.issn.2095-5227.2024.089.
[33]	LIU Y, LI SQ, LI S, et al. Correlation of platelet-lymphocyte ratio and neutrophil-lymphocyte ratio with prognosis of liver failure[J]. Chin J Gastroenterol Hepatol, 2019, 28( 5): 546- 551. DOI: 10.3969/j.issn.1006-5709.2019.05.014. 刘影, 李淑芹, 李莎, 等. 血小板/淋巴细胞比值和中性粒细胞/淋巴细胞比值与肝衰竭预后相关性研究[J]. 胃肠病学和肝病学杂志, 2019, 28( 5): 546- 551. DOI: 10.3969/j.issn.1006-5709.2019.05.014.
[34]	LI D, SUN W, CHEN L, et al. Utility of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in predicting acute-on-chronic liver failure survival[J]. Open Life Sci, 2023, 18( 1): 20220644. DOI: 10.1515/biol-2022-0644.
[35]	XU ZP, ZHANG J, ZHONG YX, et al. Predictive value of the monocyte-to-lymphocyte ratio in the diagnosis of prostate cancer[J]. Medicine, 2021, 100( 38): e27244. DOI: 10.1097/MD.0000000000027244.
[36]	WANG Q, QIAO WY, LIU BY, et al. The monocyte to lymphocyte ratio not only at baseline but also at relapse predicts poor outcomes in patients with hepatocellular carcinoma receiving locoregional therapy[J]. BMC Gastroenterol, 2022, 22( 1): 98. DOI: 10.1186/s12876-022-02180-6.
[37]	LI XW, ZHANG LY, DU YY, et al. Association between monocyte-to-lymphocyte ratio and cardiovascular diseases: Insights from NHANES data[J]. Diabetol Metab Syndr, 2025, 17( 1): 98. DOI: 10.1186/s13098-025-01640-9.
[38]	LIU XY, HE X, CAI M, et al. Prognostic value of complete blood cell count-derived inflammatory markers in hepatitis B virus-related acute-on-chronic liver failure[J]. Clin Lab, 2021, 67( 10). DOI: 10.7754/Clin.Lab.2021.210217. DOI: 10.7754/Clin.Lab.2021.210217.
[39]	WANG N, HE SK, ZHENG Y, et al. The value of NLR versus MLR in the short-term prognostic assessment of HBV-related acute-on-chronic liver failure[J]. Int Immunopharmacol, 2023, 121: 110489. DOI: 10.1016/j.intimp.2023.110489.
[40]	HU B, YANG XR, XU Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma[J]. Clin Cancer Res, 2014, 20( 23): 6212- 6222. DOI: 10.1158/1078-0432.CCR-14-0442.
[41]	HONG YM, YOON KT, CHO M. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma[J]. BMC Cancer, 2021, 21( 1): 569. DOI: 10.1186/s12885-021-08124-9.
[42]	LEE CH, YEN TH, HSIEH SY. Outcomes of geriatric patients with hepatocellular carcinoma[J]. Curr Oncol, 2022, 29( 6): 4332- 4341. DOI: 10.3390/curroncol29060346.
[43]	MAI MY, YANG FF, GU XJ. Research progress on the significance of systemic immune-inflammation index in the evaluation of immune inflammatory disease[J]. Clin Res Prac, 2024, 9( 1): 189- 193. DOI: 10.19347/j.cnki.2096-1413.202401044. 麦铭燕, 杨发奋, 古贤君. 全身免疫炎症指数对免疫炎症性疾病评价意义的研究进展[J]. 临床医学研究与实践, 2024, 9( 1): 189- 193. DOI: 10.19347/j.cnki.2096-1413.202401044.
[44]	YANG RN, CHANG Q, MENG XC, et al. Prognostic value of Systemic immune-inflammation index in cancer: A meta-analysis[J]. J Cancer, 2018, 9( 18): 3295- 3302. DOI: 10.7150/jca.25691.
[45]	KIM T, SIM J, HONG SY, et al. Systemic immune-inflammatory marker of high meld patients is associated with early mortality after liver transplantation[J]. Transplant Proc, 2021, 53( 10): 2945- 2952. DOI: 10.1016/j.transproceed.2021.09.039.
[46]	HE XC, LIN YH, QIU HY, et al. Predictive effect of systemic immune inflammatory index combined with neutrophil-to-lymphocyte ratio on prognosis of patients with acute-on-chronic liver failure[J]. Am J Transl Res, 2023, 15( 12): 6841- 6848.
[47]	YOU L, HAN L. Study on correlation between SIRI, SII, liver fibrosis level and poor prognosis in elderly patients with chronic and subacute liver failure[J]. Geriatr Health Care, 2024, 30( 4): 925- 929, 940. DOI: 10.3969/j.issn.1008-8296.2024.04.007. 尤丽, 韩丽. 老年慢加亚急性肝衰竭患者SIRI、 SII、肝纤维化水平特征与不良预后的相关性研究[J]. 老年医学与保健, 2024, 30( 4): 925- 929, 940. DOI: 10.3969/j.issn.1008-8296.2024.04.007.
[48]	QIANG L, QIN J, SUN C, et al. A novel predictive model based on inflammatory markers to assess the prognosis of patients with HBV-related acute-on-chronic liver failure: a retrospective cohort study[J]. BMC Gastroenterol, 2020, 20( 1): 301. DOI: 10.1186/s12876-020-01437-2.
[49]	CAI JJ, WANG K, HAN T, et al. Evaluation of prognostic values of inflammation-based makers in patients with HBV-related acute-on-chronic liver failure[J]. Medicine, 2018, 97( 46): e13324. DOI: 10.1097/MD.0000000000013324.
[50]	LIU XH, YANG SJ, LIU YS, et al. Value of peripheral blood lymphocyte count in evaluating the short-term prognosis of patients with acute-on-chronic liver failure[J]. J Clin Hepatol, 2023, 39( 10): 2383- 2389. DOI: 10.3969/j.issn.1001-5256.2023.10.016. 刘小花, 杨淑娟, 刘瑜珊, 等. 外周血淋巴细胞计数在慢加急性肝衰竭短期预后评估中的价值[J]. 临床肝胆病杂志, 2023, 39( 10): 2383- 2389. DOI: 10.3969/j.issn.1001-5256.2023.10.016.